Intellipharmaceutics International Inc
TSX:IPCI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intellipharmaceutics International Inc
Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company is headquartered in Etobicoke, Ontario. The firm is specializing in the research, development and manufacture of generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products and product candidates in various stages of development, in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its Paradoxical OverDose Resistance Activating System (PODRAS) delivery technology is designed to prevent overdose when more pills than prescribed are swallowed intact. Its product and product candidates include Generic Focalin XR, Generic Keppra XR, Generic Glucophage XR and Generic Effexor XR, among others.
Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company is headquartered in Etobicoke, Ontario. The firm is specializing in the research, development and manufacture of generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products and product candidates in various stages of development, in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its Paradoxical OverDose Resistance Activating System (PODRAS) delivery technology is designed to prevent overdose when more pills than prescribed are swallowed intact. Its product and product candidates include Generic Focalin XR, Generic Keppra XR, Generic Glucophage XR and Generic Effexor XR, among others.
